Cannabis Use Increases Risk of Death, Heart Attack for ED Patients

Why It Matters

The elevated mortality and heart‑attack risk linked to cannabis use could reshape emergency‑department screening protocols and influence public‑health messaging around marijuana consumption.

Key Takeaways

• Study analyzed 1.7 million ED visits from 2005‑2022.
• Cannabis‑use disorder linked to 69% higher three‑year mortality.
• MI risk rose 7% among patients with recent cannabis use.
• Stroke rates showed no significant difference between cannabis users and controls.
• Findings may prompt clinicians to screen for cannabis use in ED.

Pulse Analysis

Cannabis remains one of the most widely consumed psychoactive substances, with an estimated 147 million users worldwide—roughly 2.5 % of the adult population. While legalization spreads across U.S. states, the medical community continues to debate its cardiovascular safety. Earlier meta‑analyses have produced conflicting results, leaving clinicians uncertain about how cannabis might influence heart health. The new analysis published in Cureus adds a large‑scale, real‑world perspective by leveraging emergency‑department data spanning 17 years, offering fresh insight into the long‑term risks associated with regular use.

The investigators performed propensity‑matched comparisons on two cohorts of about 300,000 adults each, isolating patients who had documented cannabis‑use disorder within five years before or one month after an ED visit. Over a three‑year follow‑up, mortality rose from 1.7 % in the control group to 2.9 % among cannabis users—a relative risk of 1.69 that reached statistical significance. Myocardial‑infarction rates increased modestly from 0.85 % to 0.91 %, while stroke incidence remained unchanged. These patterns suggest that cannabis may exacerbate fatal cardiovascular events more than previously recognized, even if its impact on stroke is limited.

For emergency physicians, the findings argue for routine substance‑use screening and heightened awareness of cardiac symptoms in patients reporting recent cannabis consumption. Health systems might consider integrating brief counseling on cardiovascular risk into discharge protocols, especially for younger adults who perceive marijuana as harmless. Policymakers and public‑health officials could use the data to refine education campaigns that balance legalization benefits with potential health costs. Further research should explore dose‑response relationships, the role of vaping versus smoking, and whether specific cannabinoids drive the observed mortality increase.